Heart transplantation in patients with treated breast carcinoma.
Since 1987, five women with end-stage cardiomyopathy and a history of treated breast carcinoma have undergone transplantation at our institution. All patients underwent extensive multidisciplinary pretransplantation evaluation to rule out metastatic disease. Disease-free interval before heart transplantation ranged from 5 to 11 years (mean, 7.6 years). All patients received immunosuppression in accordance with a standard protocol of rabbit antithymocyte globulin, cyclosporine, prednisone, and azathioprine. Mean postoperative follow-up is 49 months. All patients are alive and have no symptoms 18 to 73 months after transplantation. In carefully selected patients with a history of breast carcinoma, heart transplantation can be performed with good functional results and satisfactory late survival.
Rosado
L J
LJ
Section of Cardiovascular and Thoracic Surgery, University of Arizona Health Sciences Center, Tucson 85724.
Wild
J C
JC
Huston
C L
CL
Sethi
G K
GK
Copeland
J G
JG
D000328:Adult; D001706:Biopsy; D001943:Breast Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003131:Combined Modality Therapy; D004699:Endocardium / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy / Q000473:pathology; D006333:Heart Failure / Q000473:pathology / Q000601:surgery*; D016027:Heart Transplantation / Q000473:pathology; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D015411:Mastectomy, Modified Radical; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology; D010348:Patient Care Team; D011183:Postoperative Complications / Q000473:pathology / Q000601:surgery*
D007166:Immunosuppressive Agents